Predictive Oncology Return on Equity

Predictive Oncology (POAI) currently reports a ROE of -671.41%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Predictive Oncology's ROE history and peer comparisons.

Predictive Oncology's ROE of -671.41% is lower than the Healthcare sector average of 21.28%. That is roughly 3255.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Predictive Oncology's current -671.41% should be judged against Healthcare norms (sector average: 21.28%) and against POAI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -671.41%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Predictive Oncology, and consider following POAI for alerts when major investors trade the stock.

Predictive Oncology is classified in the Healthcare sector. On ROE, it currently shows -671.41% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing POAI with unrelated industries.